The FDA and oncology: 2023 year in review

As we round the corner into the last few weeks of 2023, AgencyIQ has taken a look back at a very busy year for the FDA’s oncology staff, and for sponsors. By our count, the FDA’s Oncologic Drugs Advisory Committee held seven meetings in 2023; additionally, the Oncology Center of Excellence authored nine new (draft) and six final guidance documents. Read on for a deep dive into the major themes in oncology this past year.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap